BR112020022961A2 - inibidores de furina - Google Patents
inibidores de furina Download PDFInfo
- Publication number
- BR112020022961A2 BR112020022961A2 BR112020022961-0A BR112020022961A BR112020022961A2 BR 112020022961 A2 BR112020022961 A2 BR 112020022961A2 BR 112020022961 A BR112020022961 A BR 112020022961A BR 112020022961 A2 BR112020022961 A2 BR 112020022961A2
- Authority
- BR
- Brazil
- Prior art keywords
- methyl
- pyridin
- piperidin
- dichlorophenyl
- oxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670050P | 2018-05-11 | 2018-05-11 | |
| US62/670,050 | 2018-05-11 | ||
| PCT/EP2019/062098 WO2019215341A1 (en) | 2018-05-11 | 2019-05-10 | Furin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020022961A2 true BR112020022961A2 (pt) | 2021-02-17 |
Family
ID=66597541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020022961-0A BR112020022961A2 (pt) | 2018-05-11 | 2019-05-10 | inibidores de furina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11773078B2 (https=) |
| EP (1) | EP3790871B1 (https=) |
| JP (1) | JP7350061B2 (https=) |
| KR (1) | KR102823187B1 (https=) |
| CN (1) | CN112384509B (https=) |
| AU (1) | AU2019267166C1 (https=) |
| BR (1) | BR112020022961A2 (https=) |
| CA (1) | CA3099863A1 (https=) |
| IL (2) | IL278642B2 (https=) |
| MX (1) | MX2020012034A (https=) |
| SG (1) | SG11202010914YA (https=) |
| WO (1) | WO2019215341A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020022961A2 (pt) | 2018-05-11 | 2021-02-17 | Glaxosmithkline Intellectual Property Development Limited | inibidores de furina |
| KR20220104744A (ko) * | 2019-11-12 | 2022-07-26 | 비피 애셋 브이, 인크. | 감염성 질환을 치료하기 위한 소분자 푸린 억제제 |
| WO2021097002A1 (en) * | 2019-11-12 | 2021-05-20 | Bp Asset V, Inc. | Use of pyridyloxypyrimidines for treating infectious diseases |
| WO2021097008A1 (en) * | 2019-11-12 | 2021-05-20 | Bp Asset V, Inc. | Use of pyridyloxypyridines for treating infectious diseases |
| KR20220167296A (ko) * | 2020-04-02 | 2022-12-20 | 비피 애셋 브이, 인크. | 코로나바이러스 감염을 치료하기 위한 푸린 억제제 |
| FR3110345B1 (fr) | 2020-05-21 | 2024-03-29 | Agence Francaise Pour Le Dev D’Al Ula | Hydrolysat de protéines du tourteau des graines de Moringa peregrina pour son application en tant que médicament, son procédé d’obtention et compositions pharmaceutiques, dermatologiques et cosmétiques. |
| CN117222410A (zh) * | 2021-02-03 | 2023-12-12 | Bp资产V股份有限公司 | 用于吸入的弗林蛋白酶抑制剂的制剂 |
| CN114853640A (zh) * | 2022-05-12 | 2022-08-05 | 马鞍山昂扬新材料科技有限公司 | 2-溴乙基磺酸钠的制备方法 |
| EP4594312A1 (en) * | 2022-09-29 | 2025-08-06 | BP Asset V, Inc. | 4-((2-(3,5-dichlorophenyl)-6-((pyrimidin-5-yl)oxy)pyridin-4-yl)methyl)piperazine derivatives as furin inhibitors and uses thereof |
| DE102023126563A1 (de) * | 2023-09-28 | 2025-04-03 | Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts | Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung |
| CN119119096B (zh) * | 2024-09-09 | 2025-09-16 | 郑州药领医药科技有限公司 | 一种4-((4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)甲基)哌啶-1-甲酸叔丁酯的合成方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
| EA013811B1 (ru) | 2002-11-21 | 2010-08-30 | Новартис Вэксинес Энд Дайэгностикс, Инк. | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака |
| US8455489B2 (en) | 2003-11-10 | 2013-06-04 | Exelixis, Inc. | Substituted pyrimidine compositions and methods of use |
| AU2005334458B9 (en) * | 2004-07-23 | 2012-06-07 | Smith, Judith | Furin inhibitors |
| AU2005284904A1 (en) | 2004-09-13 | 2006-03-23 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| EP2478766A3 (en) | 2007-05-09 | 2012-08-15 | Burnham Institute for Medical Research | Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens |
| JP5328816B2 (ja) | 2008-02-22 | 2013-10-30 | エフ．ホフマン−ラ ロシュ アーゲー | アミロイドβの調節薬 |
| SG189019A1 (en) | 2010-10-18 | 2013-05-31 | Cerenis Therapeutics Holding Sa | Compounds, compositions and methods useful for cholesterol mobilisation |
| US9266828B2 (en) * | 2012-03-16 | 2016-02-23 | Sanford-Burnham Medical Research Institute | Inhibitors of Furin and other pro-protein convertases |
| US20150051138A1 (en) | 2012-03-16 | 2015-02-19 | Sanford-Burnham Medical Research Institute | Inhibitors of furin and other pro-protein convertases |
| US9353066B2 (en) | 2012-08-20 | 2016-05-31 | Merck Sharp & Dohme Corp. | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors |
| US10150742B2 (en) | 2013-03-15 | 2018-12-11 | President And Fellows Of Harvard College | Substituted heterocyclic compounds for treating or preventing viral infections |
| EP3265445B1 (en) | 2015-03-06 | 2021-05-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| CN107441094B (zh) | 2017-08-08 | 2020-05-22 | 南方医科大学 | 尼罗替尼作为治疗登革病毒感染的药物及其制药用途 |
| BR112020022961A2 (pt) | 2018-05-11 | 2021-02-17 | Glaxosmithkline Intellectual Property Development Limited | inibidores de furina |
| KR20220104744A (ko) | 2019-11-12 | 2022-07-26 | 비피 애셋 브이, 인크. | 감염성 질환을 치료하기 위한 소분자 푸린 억제제 |
-
2019
- 2019-05-10 BR BR112020022961-0A patent/BR112020022961A2/pt unknown
- 2019-05-10 WO PCT/EP2019/062098 patent/WO2019215341A1/en not_active Ceased
- 2019-05-10 US US17/054,491 patent/US11773078B2/en active Active
- 2019-05-10 MX MX2020012034A patent/MX2020012034A/es unknown
- 2019-05-10 IL IL278642A patent/IL278642B2/en unknown
- 2019-05-10 IL IL302997A patent/IL302997B2/en unknown
- 2019-05-10 KR KR1020207035245A patent/KR102823187B1/ko active Active
- 2019-05-10 CN CN201980046497.1A patent/CN112384509B/zh active Active
- 2019-05-10 CA CA3099863A patent/CA3099863A1/en active Pending
- 2019-05-10 SG SG11202010914YA patent/SG11202010914YA/en unknown
- 2019-05-10 AU AU2019267166A patent/AU2019267166C1/en active Active
- 2019-05-10 JP JP2021513005A patent/JP7350061B2/ja active Active
- 2019-05-10 EP EP19725058.2A patent/EP3790871B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL278642B2 (en) | 2023-10-01 |
| EP3790871A1 (en) | 2021-03-17 |
| SG11202010914YA (en) | 2020-12-30 |
| WO2019215341A1 (en) | 2019-11-14 |
| AU2019267166C1 (en) | 2023-11-30 |
| IL278642B1 (en) | 2023-06-01 |
| IL302997A (en) | 2023-07-01 |
| AU2019267166B2 (en) | 2023-06-15 |
| US11773078B2 (en) | 2023-10-03 |
| IL302997B1 (en) | 2024-04-01 |
| KR102823187B1 (ko) | 2025-06-20 |
| AU2019267166A1 (en) | 2020-11-26 |
| KR20210021298A (ko) | 2021-02-25 |
| IL302997B2 (en) | 2024-08-01 |
| EP3790871C0 (en) | 2024-01-24 |
| US20220315556A1 (en) | 2022-10-06 |
| IL278642A (https=) | 2020-12-31 |
| EP3790871B1 (en) | 2024-01-24 |
| CN112384509B (zh) | 2024-04-30 |
| JP2021523941A (ja) | 2021-09-09 |
| MX2020012034A (es) | 2021-04-12 |
| CN112384509A (zh) | 2021-02-19 |
| CA3099863A1 (en) | 2019-11-14 |
| JP7350061B2 (ja) | 2023-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020022961A2 (pt) | inibidores de furina | |
| AU2023216887B2 (en) | Compounds and methods for the targeted degradation of androgen receptor | |
| EP2970242B1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| US6297232B1 (en) | Triazolo[4,5-D]pyrimidinyl derivatives and their use as medicaments | |
| ES2706745T3 (es) | Compuestos de aminopiridazinona como inhibidores de proteína cinasa | |
| SG11202112336PA (en) | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | |
| JP2021523941A5 (https=) | ||
| SA520411465B1 (ar) | مركبات فعّالة علاجياً وطرق استخدامها | |
| EA025183B1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh | |
| KR20180063138A (ko) | 아시네토박터 바우만니이에 대항하는 펩티드 거대고리 | |
| IL323347A (en) | Chemical compounds | |
| US12172984B2 (en) | Pyrazolopyridine derivatives and uses thereof | |
| US20240383905A1 (en) | Fgfr inhibitors and methods of use thereof | |
| WO2024028169A1 (en) | Novel specifically substituted thiophenolic compounds | |
| EP4653436A1 (en) | Heterocyclic compounds, preparation method therefor and use thereof | |
| ES3036245T3 (en) | Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer | |
| JP2023503852A5 (https=) | ||
| WO2016128140A1 (en) | Pyrimidine derivatives for use in the treatment of cancer | |
| RU2020140798A (ru) | Ингибиторы фурина | |
| RU2799824C2 (ru) | Ингибиторы фурина | |
| HK40047035B (en) | Furin inhibitors | |
| HK40047035A (en) | Furin inhibitors | |
| US20230365531A1 (en) | Inhibitors of human respiratory syncytial virus and metapneumo virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) |